Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis



Status:Completed
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:12/8/2018
Start Date:September 13, 2010
End Date:October 19, 2018

Use our guide to learn which trials are right for you!

A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis

The purpose of this study is to collect long-term safety and tolerability, long-term
efficacy, and health outcome data in all patients currently ongoing in the fingolimod
multiple sclerosis clinical development program. This study will combine all currently
ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned
studies into one single long-term extension protocol that will provide patients with
continuous treatment and will continue until fingolimod is registered, commercially
available, and reimbursed in the respective countries.


Inclusion Criteria:

- Patients who have completed selected ongoing or planned trials with FTY720.

Exclusion Criteria:

- Premature permanent discontinuation of a previous fingolimod study.

- Pregnant or nursing (lactating) women.

- Women of child-bearing potential, UNLESS they are using two birth control methods, at
least 1 of which must be hormonal contraception, tubal sterilization, partner's
vasectomy or intrauterine device.

- Chronic disease of the immune system, other than multiple sclerosis, which may require
immunosuppressive treatment.

- Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or
proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c > 8%.

- Active systemic bacterial, viral or fungal infections, or known to have AIDS,
Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface
antigen or Hepatitis C antibody tests.

- Previous treatment with cladribine, cyclophosphamide or mitoxantrone.

- Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in
the past 3 months during the previous fingolimod study:

- Any of the following cardiovascular conditions that have developed during the previous
fingolimod study:

- Myocardial infarction within the past 6 months prior to entry in the extension
study or with current unstable ischemic heart disease;

- Cardiac failure (Class III, according to New York Heart Association
Classification) or any severe cardiac disease as determined by the investigator;

- Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g.,
amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)

- History or presence of a third degree AV block

- Proven history of sick sinus syndrome or sino-atrial heart block

- Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon

- Any of the following pulmonary conditions during the previous fingolimod study:

- Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous
fingolimod study)

- Active tuberculosis

- Alcohol abuse, chronic liver disease during the previous fingolimod study.

The patient must have participated in a previous fingolimod trial to be eligible to
participate in this trial.

Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
35
sites
Sacramento, California 95825
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21287
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Baltimore, Maryland 21287
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bristol, Tennessee 37620
?
mi
from
Bristol, TN
Click here to add this to my saved trials
Burlington, Vermont 05401
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Caba, Buenos Aires
?
mi
from
Caba,
Click here to add this to my saved trials
Charlottesville, Virginia 22904
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Cullman, Alabama 35058
?
mi
from
Cullman, AL
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Kansas 66160
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Kansas City, Missouri 64111
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Lenexa, Kansas 66212
?
mi
from
Lenexa, KS
Click here to add this to my saved trials
Maitland, Florida 32751
?
mi
from
Maitland, FL
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Nashville, Tennessee 37205
?
mi
from
Nashville, TN
Click here to add this to my saved trials
230 Park Avenue, 21st Floor
New York, New York 10169
1-888-669-6682)
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oceanside, California 92056
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15224
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pompano Beach, Florida 33060
?
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Raleigh, North Carolina 27609
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
San Antonio, Texas 78207
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98103
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tallahassee, Florida 32308
?
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Tampa, Florida 33613
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Toledo, Ohio 43606
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Tualatin, Oregon 97062
?
mi
from
Tualatin, OR
Click here to add this to my saved trials
Tulsa, Oklahoma 74104
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Vero Beach, Florida 32960
?
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials